Matthew W. Strobeck - 02 Jan 2026 Form 4 Insider Report for BIODESIX INC (BDSX)

Reporting relationship: Director
Issuer ticker: BDSX
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 16:27:01 UTC
Prior SEC filing: 02 Jun 2025
Next SEC filing: 13 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Robin H. Cowie as Attorney-in-Fact for Matthew Strobeck

Key filing fact

Matthew W. Strobeck filed Form 4 for BIODESIX INC (BDSX) on 06 Jan 2026.

Key facts

This page summarizes Matthew W. Strobeck's Form 4 filing for BIODESIX INC (BDSX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 06 Jan 2026, 16:27.

Change

Previous filing in this sequence was filed on 02 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001377832 Primary reporting owner

Strobeck Matthew

Relationship: Director
Address: 919 WEST DILLON RD, LOUISVILLE
Signature: /s/ Robin H. Cowie as Attorney-in-Fact for Matthew Strobeck
Signature date: 06 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BDSX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +6,804
Change %
Price: $0.000000
Shares after: 6,804
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,804
Exercise price
Footnotes: F1, F2, F3

BDSX transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +6,354
Change %
Price: $0.000000
Shares after: 6,354
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,354
Exercise price: $6.46
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").

Footnote F2

These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Footnote F3

Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.

Footnote F4

This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.